编辑精选——每日远程缺血预适应治疗间歇性跛行:一项假对照随机试验
这项单中心、平行、随机、假对照、双盲试验于2022年1月至2023年4月在门诊开展,42例稳定间歇性跛行(Fontaine IIa或IIb期)患者随机接受28天远程缺血预适应(RIPC)或假干预。预设主要结局为28天后跑步机测量的最大步行距离(MWD)变化。结果显示,MWD变化>10%者在RIPC组为14例,假组为8例(相对风险1.37,95%置信区间0.74-2.25;P=0.35),间歇性跛行距离、跛行缓解时间和健康相关生活质量组间差异均无统计学意义。
要点
- 28天RIPC未显著改善间歇性跛行患者的最大步行距离。
- MWD变化>10%者RIPC组14例 vs 假组8例(相对风险1.37,95%CI 0.74-2.25;P=0.35)。
- 间歇性跛行距离、跛行缓解时间和健康相关生活质量组间差异无统计学意义。
核心结论
- 在这项试验中,与假设备治疗相比,RIPC未显著改善最大步行距离、间歇性跛行距离或跛行缓解时间。
研究设计与样本
- 单中心、平行、随机、假对照、双盲试验,于2022年1月至2023年4月在门诊开展。
- 42例稳定间歇性跛行(Fontaine IIa或IIb期)患者随机接受RIPC或假干预28天。
- 预设主要结局为28天后跑步机测量的最大步行距离变化,MWD变化>10%视为有临床意义。
- 次要结局为间歇性跛行距离、跛行缓解时间和VascuQoL-6问卷测量的健康相关生活质量(ClinicalTrials.gov ID: NCT05084066)。
主要发现
- 分析41例男性(RIPC组23例,假组18例),年龄64.9±7.4岁。
- MWD变化>10%者RIPC组14例 vs 假组8例(相对风险1.37,95%置信区间0.74-2.25;P=0.35)。
- 间歇性跛行距离、跛行缓解时间和健康相关生活质量组间差异均无统计学意义。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Remote ischaemic preconditioning (RIPC) is a promising non-invasive strategy in which brief episodes of ischaemia and reperfusion can increase skeletal muscle resistance to ischaemia and improve mobility. This study aimed to determine whether 28 consecutive days of RIPC improved intermittent claudication (IC) symptoms compared with sham intervention. METHODS: This single centre, parallel, randomised, sham controlled, double blind trial was conducted from January 2022 to April 2023 in outpatient settings. Forty two patients with stable IC Fontaine stage IIa or IIb were randomised to RIPC or sham for 28 days. The pre-specified primary outcome was a change in the maximum walking distance (MWD) after 28 days measured with a treadmill test. A > 10% change in MWD was considered clinically significant. Change in intermittent claudication distance (ICD), time to relief from claudication (TRC), and health related quality of life (HRQoL) measured with the VascuQoL-6 questionnaire were the secondary outcomes (ClinicalTrials.gov ID: NCT05084066). RESULTS: Forty one men (RIPC = 23, sham = 18) aged 64.9 ± 7.4 years were analysed. A change of > 10% in MWD occurred in 14 patients in the RIPC group vs. eight patients in the sham group (relative risk 1.37, 95% confidence interval 0.74 - 2.25; p = .35). Changes in ICD, TRC, and HRQoL between the groups were not statistically significant. CONCLUSION: In this trial, RIPC did not significantly improve MWD, ICD, or TRC compared with treatment with a sham device.
引用
- Eerik K, Kasepalu T, Post H, et al. Editor's Choice - Daily Remote Ischaemic Preconditioning for Intermittent Claudication: A Sham Controlled Randomised Trial. Eur J Vasc Endovasc Surg. 2024. PMID: 39522584. doi:10.1016/j.ejvs.2024.10.047
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。